drugset
drugset / Trial / NCT03161548

A Study of Tongue Conservation Surgery for Oral Tongue Cancer

NCT03161548 ↗

Phase 2 Terminated 23 enrolled Taipei Veterans General Hospital, Taiwan
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-comparative phase II clinical trial to assess efficacy and safety of tongue conservation treatment with sequential induction chemotherapy, tongue conservation surgery and postoperative concurrent chemoradiotherapy (CCRT) in patients with advanced oral tongue cancer.

Timeline

Start
2011-07-18
Primary completion
2016-01-27
Completion
2017-01-04

Outcome

Outcome not reported

Stopped (Enrollment): “Diffiult patient recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Docetaxel Small molecule 36 mg/m2 Intravenous
Subject Tegafur/uracil Unknown 200 mg Oral
Background Leucovorin Small molecule 90 mg —

Indications

chemotherapy-induced toxicity tongue cancer